





















































































































































































































































































































































































































































































































































































































































































































































	 	 	 Prelaminar/	
laminar		
Retrolaminar		 Transection	 Non-massive		 Massive		 	 	
Primary	enucleation	
1	 LE	 -	 	 +	 -	 -	 -	 -	 pT3bNxM0	
2	 LE	 -	 	 +	 -	 +	 -	 -	 pT3bNxM0	
3	 RE	 -	 +	 	 -	 	 +	 -	 pT3aNxM0	
4	 RE	 -	 -	 -	 -	 	 +	 -	 pT3aNxM0	




-	 -	 -	 -	 -	 -	 pT2bNxM0	
7	 RE	 CB	&	iris	 -	 -	 -	 -	 -	 -	 pT2bNxM0	






-	 -	 -	 	 +	 -	 pT3aNxM0	








	 	 D	 E	 D	 E	 	
8Wilson	et	al.	 2011	 47	(70)	 20	(30)	 6	(13)	 10	(50)	 IIRC	group	E	
9Kaliki	et	al.	 2015	 50	(12)	 353	(88)	 8	(16)	 137	(39)	 prolonged	duration	of	
symptoms	of	>6	months	and	
secondary	glaucoma	
*11Yousef	et	al.	 2015	 24	(57)	 18	(43)	 8	(33)	 11	(61)	 clinical	TNM		edition	th7	igherH
stage	and	more	advanced	ICRB	
group	(i.e.,	group	E	eyes)	
**	10Brennan	et	al.	 2015	 54	(39)	 86	(61)	 8	(15)	 37	(43)	 NA	
	12Kaliki	et	al.	 2013	 87	(17)	 432	(83)	 15	(17)	 102	(24)	 NA	
Fabian	et	al.	
(present	study)	
2016	 40	(100)	 -	 5	(13)	 -	 Absence	of	vitreous	seeds	at	
presentation	
1International	Intraocular	Retinoblastoma	Classification.	–IIRC		
*	Eight	IIRC	group	C	were	also	included	in	the	study,	in	1	of	which	HRH	features	were	detected.		
**	One	IIRC	group	B	and	1	group	C	were	also	included	in	the	study,	in	addition	to	2	cases	in	which	IIRC	grouping	
was	not	available.	In	one	of	the	latter	cases,	HRH	features	were	detected.		
	
Supplemental	Digital	Table	1.		Primary	versus	secondary	enucleation	in	64	group	D	eyes:	
demographic,	clinical	variables,	genetic	analysis	and	classification	according	to	the	8th	edition	
cTNMH	Retinoblastoma	Staging.18	
Parameter	 Primary	enucleation		
N=40	patients	(%)	
N=40	eyes	(%)	
Secondary	enucleation		
N=22	patients	(%)	
N=24	eyes	(%) 
Gender	
										Male		
										Female	
	
22	(55)	
18	(45)	
	
14	(64)	
8	(36)	
Uni/bilateral	retinoblastoma	
										Unilateral	at	presentation		
										Bilateral	at	presentation	
	
37	(93)	
3	(7)	
	
6	(28)	
16	(72)	
Age	of	diagnosis	(months)	
										Median	(mean,	range)	
	
24.0	(23.7,	1.0-60.0)	
	
12.5	(8.8,	0.6-144.0)	
Family	history	of	retinoblastoma	
											Negative	(sporadic)	
											Positive	(familial)	
	
40	(100)	
0	(0)	
	
17	(77)	
5	(23)	
RB1	Blood	mutation	
										Negative	
										Positive	
	
32	(80)	
8	(20)	
	
6	(27)	
16	(73)	
Tumour	focality		
										Unifocal	
										Multifocal	
	
39	(98)	
1	(2)	
	
19	(79)	
5	(21)	
Tumour	dimensions	(mm)	
										Median	(mean,	range)	
	
	
	
	
Risk	Group	D	Retinoblastoma-High	/et	al.		Fabian	
	
20	
	
																				Height	
																				Base	
10.4	(10.4,	6.9-13.7)	
14.2	(14.1,	9.2-17.5)	
11.5	(10.8,	5.1-13.9)	
14.3	(13.6,	8.8-16.2)	
Quadrants	of	retinal	detachment	
										No	detachment	
										Local	
										1	
										2	
										3	
										4	
	
2	(5)	
6	(15)	
3	(8)	
3	(8)	
8	(20)	
18	(45)	
	
0	(0)	
4	(17)	
1	(4)	
3	(13)	
2	(8)	
14	(58)	
Retinoblastoma	growth	pattern	
										Endophytic	
										Exophytic	
	
22	(55)	
18	(45)	
	
14	(58)	
10	(42)	
Optic	disc	obscured	
										Not	obscured	
										Obscured	
	
2	(5)	
38	(95)	
	
4	(17)	
20	(83)	
Fovea	involvement	
										Not	involved	
										Sub-foveal	fluid	
										Foveal	tumour	
	
2	(5)	
6	(15)	
32	(80)	
	
3	(13)	
5	(21)	
16	(67)	
Retinoblastoma	seeds	
										No	seeds	
										Sub-retinal	
										Vitreous	
	
0	(0)	
15	(38)	
14	(35)	
	
3	(13)	
7	(29)	
15	(63)	
8th	edition	cTNMH	
									cT2bN0M0H0	
										cT2bN0M0H1	
										cT2aN0M0H0	
										cT2aN0M0H1	
	
32	(50%)	
8	(13%)	
0	(0%)	
0	(0%)	
	
5	(8%)	
16	(25%)	
0	(0%)	
3	(5%)	
Time	to	enucleation	(months)	
										Median	(mean,	range)	
	
0.2	(0.3,	0.2-1.4)	
	
16.2	(23.7,	2.6,	91.0)	
Total	follow-up	time	(months)	
										Median	(mean,	range)	
	
73.2	(68.8,	19.0-124.9)	
	
73.2	(76.1,	13.7-153.0)	
	
